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ABSTRACT
Introduction: The use of repeated thermal
therapy for improving the symptoms of
chronic heart failure (CHF) has been recently
demonstrated. Usually, thermal therapy
requires an infrared dry sauna. However, it is
difficult for small clinics to acquire such an
expensive and extensive system. The present
study assessed the efficacy of its substitution
with hot water bottles. Moreover, there are no
prior studies demonstrating the efficacy of
thermal therapy in hemodialysis patients with
CHF.
Methods: Plasma brain natriuretic peptide
(BNP) levels were evaluated in 98 hemodialysis
patients in a clinic. Nine patients whose BNP
levels were[500 pg/mL agreed to be enrolled in
the study and received thermal therapy using
hot water bottles.
Results: Plasma BNP levels, a potential marker
for CHF, tended to decrease (891 ± 448 to
680 ± 339 pg/mL), but the difference was not
significant (P = 0.0845). The oral temperature
changed from 36.44 ± 0.45C to 37.04 ± 0.48C
(?0.597C, P\0.0001). No side effects were
experienced during the therapy. Moreover,
most patients had an improvement in their
symptoms and the ability to perform activities
of daily living.
Conclusion: Thermal therapy using hot water
bottles is very safe and tends to reduce plasma
BNP levels in hemodialysis patients with CHF.
Keywords: BNP; Brain natriuretic peptide;
Chronic heart failure; Chronic kidney disease;
Hemodialysis; Hot water bottle thermal therapy
INTRODUCTION
Chronic heart failure (CHF) is a major, serious
complication for hemodialysis patients [1–3].
Kihara et al. and Miyata et al. [4–6] recently
reported that repeated thermal therapy could
improve hemodynamics and symptoms in
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patients with CHF. The therapy requires an
infrared-ray dry sauna because the temperature
needs to be maintained evenly at 60C.
Unfortunately, it is difficult for small clinics to
acquire such an expensive and extensive
system. Kihara et al. and Miyata et al. [4–6]
proposed warm water baths as a substitute for
saunas, which can warm the body without
overloading the heart.
The present study assessed whether thermal
therapy for CHF using hot water bottles can be
used as a substitute for infrared-ray dry sauna,
and whether thermal therapy is useful for
hemodialysis patients with CHF as there have
been no studies demonstrating the efficacy of
thermal therapy in this patient population.
Brain natriuretic peptide (BNP) was used to
assess left ventricular (LV) function as it is
superior to volume overload in heart failure
patients with normal kidney function [7].
A high water volume exists in hemodialysis
patients because of hypouresis.
MATERIALS AND METHODS
Study Design and Participants
The study procedures were in accordance with
the guidelines of the 2000 Declaration of
Helsinki for human experimentation. All
patients provided informed consent. Nine out
of 98 inpatients undergoing hemodialysis
treatment in November 2007 at the Hosoe
clinic, and whose BNP levels were [500 pg/mL
were enrolled in this study. Patients with
arterial ventricular stenosis and other outflow
obstacle heart disease were excluded as thermal
therapy is contraindicated in these conditions
[4, 5]. None of the nine patients had any signs,
symptoms, or history of cancer or any active
inflammatory disease.
Laboratory Measurements
To evaluate BNP levels after hemodialysis, blood
samples of the patients were collected in the
supine position. Plasma samples were prepared
within 30 min after collection using a
pre-cooled centrifuge. Extracted plasma samples
were frozen immediately and stored at -20C
until analysis. Plasma BNP concentrations were
measured by an immunoradiometric assay
specific for human BNP using a commercial kit
(Shionogi BNP kit; Shionogi Co. Ltd., Osaka,
Japan). Repeat blood samples were collected
3 months later at the end of the follow-up
period. The oral temperature was measured
before and after each therapy session.
Thermotherapy Using Hot Water Bottles
Patients were interviewed and evaluated as to
their ability to perform activities of daily living
(ADL), and heart failure was classified using the
classification of New York Heart Association
(NYHA) before and after the study.
Before the study, all patients were treated
with beta-blockers, angiotensin II-converting
enzyme inhibitors, and angiotensin II-receptor
blockers according to the treatment guidelines
for the evaluation and management of CHF [8].
Drug treatment was continued throughout the
study. After an examination that involved
measuring patients’ dry weight, and assessing
X-ray images and other clinical parameters,
such as blood pressure, patients received
thermal therapy using hot water bottles. This
therapy is derived from the thermal therapy
using an infrared-ray dry sauna invented by
Kihara et al. and Miyata et al. [4, 5]. Initially,
patients received a hot water foot bath (44C)
for 30 min. Subsequently, patients were then
asked to lie down on a bed with hot water
bottles and were wrapped in a blanket for
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another 30 min. This procedure was repeated
three times per week after hemodialysis for a
total follow-up period of 3 months.
Statistical Analysis
Values are expressed as the mean ± SD.
Student’s t test was used for all comparisons.
P values less than 0.05 were considered
significant.
RESULTS
Demographic and clinical characteristics of the
patients are summarized in Tables 1 and 2,
respectively. Before the study, the patients’
ability to perform ADL was assessed. If, despite
high BNP levels, the patients did not complain
of NYHA-defined heart failure-related
symptoms, it was speculated that it might have
been difficult for hemodialysis patients with
many co-morbidities causing pain and joint
problems to differentiate the symptoms related
to heart failure. Each patient underwent thermal
therapy three times per week after hemodialysis
for 3 months. The nine patients who were
included in the analysis (2 men and 7 women;
mean age 74.2 ± 14.6 years old; average
duration of hemodialysis 8.3 ± 6.2 years) were
able to continue thermotherapy and were
observed for 3 months. Plasma BNP levels in
the peripheral blood changed from 891 ±
448 pg/mL (range 419–1,627 pg/mL) to
680 ± 339 pg/mL (range 208–1,100 pg/mL)
after 3 months (P = 0.0845). The changes in
plasma BNP levels were not significant, but the
levels tended to decrease. The oral temperature
changed from 36.44 ± 0.45C to 37.04 ± 0.48C
(?0.597C, P\0.0001). After 3 months of
thermal therapy, the ADL score improved in all
patients (Table 2).
Other clinical parameters, such as
blood pressure, dry weight, anemia, and
cardiothoracic ratio did not change
significantly (data not shown). Results of the
echocardiogram tests conducted before and
after the study period revealed no significant
change in the ejection fraction and other
associated parameters (data not shown). No
side effects were experienced during the therapy.
DISCUSSION
Results of this study suggest that the ability of
hemodialysis patients to perform ADL can be
improved with the use of hot water bottle
Table 1 Demographic characteristics, and present heart








1 79 Female 5.0 SN/AR
moderate
2 79 Male 6.0 CGN/MR mild
3 53 Female 15.0 DM/LVH
4 83 Female 3.0 DM/OMI
5 73 Female 13.0 PKD/MR and
LVH mild
6 80 Female 5.0 DM/MR and
AR
7 47 Male 6.0 SN/MR
8 90 Female 2.0 MR/AR and
LVH
9 84 Female 20.0 PKD/MR
AF atrial ﬁbrillation, AR aortic valve regurgitation, CGN
chronic glomerular nephropathy, DM diabetic
nephropathy, LVH left ventricular hypertrophy, MR
mitral valve regurgitation, OMI old myocardial
infarction, PKD polycystic kidney disease, SN sclerosis
nephropathy
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thermal therapy, and that such therapy can
help to decrease plasma BNP levels. This is the
first study to demonstrate that mild thermal
therapy is an effective, relatively safe, and easy
way to improve the ability to perform ADL, and
may also improve LV function in CHF patients.
Thermal therapy, also known as Waon
therapy, is defined as ‘‘therapy in which the
entire body is warmed in an evenly heated
chamber for 15 min at a temperature that
soothes the mind and body, and after the deep
body has increased by approximately 1.0–1.2C,
the soothing warmth continues at rest for
an additional 30 min, with fluids supplied at
the end to replace the loss from perspiration’’
[4].
According to Kihara et al. and Miyata et al.
[4–6], although medical progress in the
twentieth century has been outstanding, there
is still no way of determining the magnitude of
a patient’s internal suffering and conflict.
Medical staff cannot appreciate the extent of
pain, tension, and stress experienced by
patients who receive life-saving therapies,
especially in the case of CHF patients who are
ineligible for operation. Kihara et al. and Miyata
et al. [4–6] developed thermal therapy for such
patients, and it has been found to improve
Table 2 Demographic characteristics of the study population and the experienced symptom change
Case Age
(years)






1 79 Female Pain in the right kneeb Disappeared II? I
2 79 Male No symptoms No change II? I
3 53 Female Chill, heart palpitation at rest Disappeared (both symptoms) II? I
4 83 Female No symptoms No change I? I
5 73 Female Right hand sclerosis (10/10); abdominal
pain after abdominal surgery (10/10); pain








6 80 Female Back pain Disappearedd NA
7 47 Male Could not speak after brain hemorrhage Became more alert and started
speakinge
NA
8 90 Female Pain in both knees Disappearedf NA
9 84 Female Pain in the left shoulder, toothache Disappearedg NA
ADL activities of daily living, NYHA New York Heart Association
a Symptoms were assessed on a scale from 1 (minimal)–10 (maximum)
b The duration of knee pain was over a year
c The patient could not walk for 100 m because of knee pain; after the study the patient could walk 3 km
d The patient could not walk and used a wheelchair; after the study the patient could walk with a cane
e The patient could not speak to complain of any symptoms for 5 years, after the study the patient could speak
f The patient could not walk because of knee pain and used a wheelchair; after the study the patient can walk with a cane
g The patient was bedridden
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hemodynamics and decrease serum BNP levels,
arrhythmia, and sympathetic nervous system
activity, which occurs with severe cardiac
failure. Moreover, this method is an effective
treatment for Sjo¨gren’s disease and other
lifestyle-related diseases, such as hypertension,
diabetes mellitus, hyperlipidemia, obesity, and
smoking-related diseases [9, 10].
Warming the body has been shown to relieve
the sympathetic nervous system [5–7].
Furthermore, it has been shown that it might
also improve the immune system [11–13].
Warming the body using hot water bottles
warms the patient slowly and does not burden
weak patients [11]. In the current medical
practice, medical staff often do not have
sufficient time to see and talk to patients.
Talking and listening to a suffering patient
enables them to relax and develop a trusting
relationship with the medical team. The time
spent with the patient by the medical staff
during the thermal treatment might be the
most important and effective part of this
therapy.
In the present study, most patients reported
alleviation of pain and the symptoms impacting
the ability to perform ADL during thermal
therapy. Warming decreases the activity of the
sympathetic nervous system and opens
peripheral blood vessels, resulting in
relaxation of tendons and muscles [4–6].
Reducing the pain also decreases the activity
of the sympathetic nervous system and
increases the patient’s trust in the medical
staff, resulting in more efficient medical care.
There are no previous studies on the
appropriate duration of thermal treatment.
The effect of sauna therapy after 2–4 weeks has
been reported [4–6], and the authors suggest
that the therapy was effective for improving the
ability to perform ADL in severe heart failure
patients when performed once a day for
3–4 days a week. In addition, this method is
very easy to implement; hence, the length of
each session can vary as required.
Measuring BNP levels is the established
parameter for assessing LV function with
normal kidney function [7]. However, there
are conflicting results concerning assessing
renal function, especially in dialysis patients.
Many reports recommend using the BNP level
as a possible prognostic marker for cardiac
disease even in chronic kidney disease (CKD)
[14–17]. Park et al. [18] recently reported that
the BNP level is a useful marker for assessing the
risk of new cardiac events in patients with CKD.
There are few reports recommending BNP levels
as a prognostic marker for CHF in CKD because
BNP levels in hemodialysis patients vary widely.
Moreover, the level of BNP in hemodialysis
patients can change daily [14, 19]. Although a
few reports suggest that the normal BNP level is
below 100 pg/dL even in hemodialysis patients
[20], other reports most commonly suggest a
range of 150–300 pg/dL for patients without
heart disease, but this level is not consistently
reported and is based on cross-sectional studies
[21, 22].
There have been no reports on longitudinal
BNP levels in hemodialysis patients. In the
present study, BNP levels in hemodialysis
patients were evaluated by means of a
longitudinal study. In most people without
CKD, BNP enhanced LV systolic and diastolic
functions. However, the most precise and
convenient method for the evaluation of
diastolic LV function remains controversial. It is
difficult to evaluate diastolic LV function using
general ultrasonography [23]. Echocardiography
was performed for all patients in the
present study, but patients’ ability to perform
ADL was very poor and correct posture could
not be obtained. Some patients also had
lung disease with severe calcification.
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Among patients on hemodialysis, there are
numerous patients with normal ejection
fraction, who also have restricted LV function
because of chronic volume overload, volume
change, hypertension, and/or amyloidosis.
The timing for measuring the BNP level is
very important. In the present study, BNP levels
were compared in the same patients at different
times. Before hemodialysis, weight gain (water
volume) values differed each time, but after
hemodialysis, dry weight values were fixed for
each patient. The BNP level was found to have
less of a relationship to water volume, but the
levels were measured before and after
hemodialysis, and were clearly different. BNP
levels were evaluated after hemodialysis. This
might be the reason that there was no
significant change in BNP levels before and
after the study. Interestingly, the BNP level
could be used as a marker for LV function in
some patients, as shown in the two patients
whose BNP levels clearly decreased in the
present study (Fig. 1). However, there is no
consensus as to the best time to measure
BNP levels in hemodialysis patients, whether it
is at the start or end of the week, or pre- or
post-hemodialysis. In the present study BNP
levels were measured after hemodialysis when
weights were fixed and other parameters were
stable. It was difficult to find the most
convenient and valid parameter to determine
heart function in hemodialysis patients. BNP
levels decreased in this study, but the decrease
was not statistically significant; however, some
patients experienced significant decreases in
BNP (Fig. 1).
There were several limitations to this study.
The number of patients was very limited and
the increase of body temperature in the study
was 0.597C, less than 1.0C suggested by
Tei et al. Furthermore, the renal impairment of
hemodialysis patients in the present study may
lead to accumulation of levels of N-terminal
proBNP [7, 15, 24, 25]. Moreover, this study
included a small population that was followed
up for a very limited duration.
Fig. 1 BNP levels before and after the present study of the two patients whose BNP clearly decreased. BNP brain
natriuretic peptide
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In conclusion, using this convenient and
simple method for thermal therapy resulted in
an improvement in patients who suffered from
pain and experienced difficulty with mobility.
The therapy also could be conducted without the
side effects associated with other effective
therapies. Thermal therapy using hot water
bottles is very safe and tends to decrease plasma
BNP levels in hemodialysis patients with CHF.
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